Pyrazine compounds

Bibliography

• LOSCHER W, SCHMIDT D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical consid-erations. Epilepsy Res. (1988) 2:145–181.
   PubMed Web of Science ®Google Scholar
• •Provides strong rationale for a defined preclinical testing hierarchy to identify new anti-epileptic drugs.
   Google Scholar
• ROGAWSKI MA, PORTER RJ: Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Rev. (1990) 42:223–286.
   PubMed Web of Science ®Google Scholar
• •Extensive review of the mechanism (s) of action of established anticonvulsant drugs.
   Google Scholar
• UPTON N: Mechanisms of action of new antiepileptic drugs: rationale design and serendipitous findings. Trends Pharmacol Sci. (1994) 15:456–463.
   PubMed Web of Science ®Google Scholar
• LOSCHER W: New visions in the pharmacology of anticonvulsion. Eur. j Pharmacol (1998) 342:1–13.
   PubMed Web of Science ®Google Scholar
• •Review of new mechanistic approaches to the development of novel anticonvulsant agents.
   Google Scholar
• WILLOW M, GONOI T, CATTERALL WA: Voltage clamp analysis of the inhibitory actions of diphenylhydan-toin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Ma Pharmacol (1985) 27:549–558.
   PubMed Web of Science ®Google Scholar
• RAGSDALE DS, SCHEUER T, CATTERALL WA: Frequency and voltage-dependent inhibition of Type HA Na channels, expressed in a mammalian cell line, by local anaesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol (1991) 40:756–765.
   PubMedGoogle Scholar
• MACLEAN MJ, MACDONALD RL: Sodium valproate, butnot ethosuximide, produces use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol Exp. Ther. (1986) 237:1001–1011.
   PubMedGoogle Scholar
• PISANI A, STEFANI A, SINISCALCHI A, MERCURI NB,BERNARDI G, CALABRESI P: Electrophysiological actions of felbamate on rat striatal neurones. Br. J. Pharmacol (1995) 116:2053–2061.
   PubMedGoogle Scholar
• ROCK DM, MACDONALD RL, TAYLOR CP: Blockade ofsustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI-912), a novel anticonvulsant. Epilepsy Res. (1989) 3:138–143.
   PubMed Web of Science ®Google Scholar
• COULTER DA, SOMBATI S, DELORENZO RJ: Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia (1993) 34 (Suppl. 2):123.
   Google Scholar
• KUO CC, LU L: Characterisation of lamotrigine inhibi-tion of Na + channels in rat hippocampal neurones. Br. Pharmacol (1997) 121:1231–1238.
   PubMed Web of Science ®Google Scholar
• ZONA C, AVOLI M: Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia (1997) 38:522–525.
   PubMed Web of Science ®Google Scholar
• LANG DG, WANG CM, COOPER BR: Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblas-toma cells. J. Pharmacol Exp. Ther. (1993) 266:829–835.
   PubMed Web of Science ®Google Scholar
• XIE XM, LANCASTER B, PEAKMAN T, GARTHWAITE J: Interaction of the antiepileptic drug lamotrigine with recombinant rat brain Type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pflagers Arch. (1995) 430:437–446.
   PubMed Web of Science ®Google Scholar
• DALE TJ, CATER H, JOHN VH, XIE XM: Comparison of the effects of the anti-convulsant drug lamotrigine with sodium valproate and gabapentin on human brain Type IIA Na+ channels expressed in a mammalian cell line. Br. J. Pharmacol (1997) 122 (Suppl.):85P.
   Google Scholar
• XIE XM, HAGAN RM: Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology (1998) 38:119–130.
   Google Scholar
• ••Comprehensive summary of mechanism of action studiesundertaken with lamotrigine.
   Google Scholar
• Lamotrigine. In: Martindale (32nd Edition). Parfitt K (Ed.), Pharmaceutical Press, London, UK (1999)347–349.
   Google Scholar
• ••Overview of current clinical utility of lamotrigine inepilepsy.
   Google Scholar
• DUNN RT, FRYE MS, KIMBRELL TA, DENICOFF KD, LEVERICH GS, POST RM: The efficacy and use of anticonvulsants in mood disorders. Clin. Neurophar-macol (1998) 21:215–235.
   PubMed Web of Science ®Google Scholar
• MCCLEANE GJ: A prospective audit of the use of lamotrigine in 300 chronic pain patients. Pain Clinic (1998) 11:97–102.
   Google Scholar
• BEGHI E: The use of anticonvulsants in neurological conditions other than epilepsy. CNS Drugs (1999) 11:61–82.
   Google Scholar
• WILD D, COX B, EDNEY D et al.: GW273293X as a potential broad spectrum anticonvulsant. 15th EFMC International Symposium on Medicinal Chemistry. Edinburgh, UK (1998):193.
   Google Scholar
• ••First public presentation on the mechanism of action andanticonvulsant profile of GW273293X.
   Google Scholar
• COX B, EDNEY D, HEALY M et al.: GW273293X: A potential broad spectrum anticonvulsant. 217th American Chemical Society Meeting Anaheim, USA (1999) MEDI280.
   Google Scholar
• LAKHAN R, BABBAN JR: Novel syntheses of heterocy-cles from alpha-oxonitriles; Part III. 2-Amino-3-arylpyrazines. Synthesis (1987) 10:914–915.
   Google Scholar
• SWINYARD EA, WOODHEAD JH, WHITE HS, FRANKLIN MR: General principles. Experimental selection, quantification, and evaluation of anticonvulsants. In: Anti-epileptic Drugs (3rd Edition). Levy R, Mattson R, Meldrum B, Penty JK, Dreifuss FE (Eds.), Raven Press Ltd., New York, USA (1989):85–102.
   Google Scholar
• TAYLOR CP, NARASIMHAN LS: Sodium channels and therapy of central nervous system diseases. Adv. Pharmacol. (1997) 39:47–98.
   PubMedGoogle Scholar
• •Overview of therapeutic opportunities for Na + channel blockers.
   Google Scholar
• WHITE HS, JOHNSON M, WOLF HH, KUPFERBERG HJ: The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. I Neurol Sci. (1995) 16:73–77.
   PubMedGoogle Scholar
• Glaxo Wellcome - Product development pipeline.Company Brochure (June 1999).
   Google Scholar